MS Morgan Stanley

NYSE
$190.02

Morgan Stanley Must Prove Its Record Run Survives a 15% Stock Slide

Morgan Stanley heads into its third-quarter report with an unusual disconnect. The firm just strung together back-to-back record quarters, crossed $10 trillion in client assets and raised its dividend 15%, yet its shares have fallen 14.6% since that July report while the S&P 500 gained 2.7%. When the bank reports before the open on October 14, the question is less whether business is good than whether the market has been right to treat the second quarter as a peak.

The Street is not asking for heroics. Consensus calls for earnings of $2.88 a share, up just 2.9% from $2.80 a year ago and well below the record $3.46 posted last quarter. The revenue estimate of roughly $19.9 billion would sit comfortably above the $18.2 billion in net revenue from the year-ago quarter but about $1.4 billion short of the second quarter's record $21.3 billion. In other words, analysts are already modeling a meaningful sequential cooldown, which is normal for a seasonally quieter summer quarter. The Earnings Whisper of $2.92 sits only modestly above consensus, suggesting the informal bar is slightly higher but not dramatically so. Management did not offer explicit quarterly guidance and reaffirmed rather than raised its firmwide targets last time, a deliberately conservative stance that leaves the numbers to do the talking.

The biggest swing factor is institutional trading. Equities produced an exceptional record $6.3 billion last quarter, with strength across products and regions, especially Asia. Repeating that is a tall order, so the real test is how gracefully it normalizes. Fixed income already showed what a giveback looks like, sliding from a post-crisis record $3.4 billion to $2.5 billion as currency volatility sat near historic lows and commodities cooled after an energy-driven first quarter. Any recovery in macro and FX activity would help cushion a softer equities print. Investment banking is where management sounded most forward-looking, describing a constructive pipeline, an IPO calendar broadening into India, Japan, Korea, Taiwan and Europe, and sponsors selectively starting to monetize holdings after a long freeze. Banking revenue holding near last quarter's $2.4 billion, with equity underwriting staying well above the depressed first-quarter level, would validate that story.

Wealth management is the steadier engine and arguably the better gauge of the long-term thesis. Net new assets hit a record $148 billion, with more than half coming from stock-plan and IPO-related flows through the workplace channel. That is a powerful funnel, but it is also tied to a hot issuance market, so investors should check whether inflows stay healthy if deal activity slows. The pre-tax margin has hovered around 30.5%; a move higher would ease concerns about efficiency, which management flagged as pressured by execution costs and heavier technology and AI spending. Watch, too, for commentary on competition from smaller advisory firms pricing aggressively for workplace business and on whether 300 basis points of excess capital translates into bolt-on deals or bigger buybacks.

Sentiment has cooled, with bullish readings slipping to 24.8% from 31.9% heading into the last report. The chart echoes that caution. At about $190, the stock sits below its 200-day moving average near $194 and closer to the bottom of its post-earnings range of roughly $182 to $232 than the top. That positioning implies investors have already priced in a good deal of normalization, which lowers the hurdle somewhat but also means a stumble could test the range low.

Ultimately, this report hinges on whether Morgan Stanley can show that its earnings power rests on durable wealth flows and a widening banking pipeline rather than one extraordinary trading quarter. Clean earnings near or above consensus, resilient net new assets and an upbeat deal outlook would argue the selloff overshot. A sharp equities retreat paired with soft banking and rising costs would suggest the market's skepticism was warranted.

← Back to MS news